Patent: 12,280,095
Summary for Patent: 12,280,095
| Title: | Tissue modifier and uses therefor |
| Abstract: | Disclosed are compositions, methods, uses, kits and articles of manufacture, which are based on the use of a hyaluronidase and a collagen-reducing agent, for reducing or inhibiting the development of fibrosis in a tissue, or for treating collagen-mediated disorders. In specific embodiments, the collagen-mediated disorders are fibroproliferative disorders involving alterations of collagen, including fibromatoses such as Dupuytren's disease. Peyronie's disease and Ledderhose's disease. |
| Inventor(s): | David Chin |
| Assignee: | Fibrosoft Pte Ltd |
| Application Number: | US18/555,377 |
| Patent Claims: | see list of patent claims |
Details for Patent 12,280,095
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Akorn, Inc. | HYDASE | hyaluronidase | Injection | 021716 | October 25, 2005 | ⤷ Start Trial | 2042-08-25 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
International Patent Family for US Patent 12,280,095
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Australia | 2022335159 | ⤷ Start Trial |
| Australia | 2024200488 | ⤷ Start Trial |
| European Patent Office | 4387653 | ⤷ Start Trial |
| European Patent Office | 4714493 | ⤷ Start Trial |
| United States of America | 2024197840 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
